Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 21;22(12):6642.
doi: 10.3390/ijms22126642.

Targeting Mitochondria in Diabetes

Nina Krako Jakovljevic  1 , Kasja Pavlovic  1 , Aleksandra Jotic  1 , Katarina Lalic  1 , Milica Stoiljkovic  1 , Ljiljana Lukic  1 , Tanja Milicic  1 , Marija Macesic  1 , Jelena Stanarcic Gajovic  1 , Nebojsa M Lalic  1
Affiliations
Review

Targeting Mitochondria in Diabetes

Nina Krako Jakovljevic et al. Int J Mol Sci. .

Abstract

Type 2 diabetes (T2D), one of the most prevalent noncommunicable diseases, is often preceded by insulin resistance (IR), which underlies the inability of tissues to respond to insulin and leads to disturbed metabolic homeostasis. Mitochondria, as a central player in the cellular energy metabolism, are involved in the mechanisms of IR and T2D. Mitochondrial function is affected by insulin resistance in different tissues, among which skeletal muscle and liver have the highest impact on whole-body glucose homeostasis. This review focuses on human studies that assess mitochondrial function in liver, muscle and blood cells in the context of T2D. Furthermore, different interventions targeting mitochondria in IR and T2D are listed, with a selection of studies using respirometry as a measure of mitochondrial function, for better data comparison. Altogether, mitochondrial respiratory capacity appears to be a metabolic indicator since it decreases as the disease progresses but increases after lifestyle (exercise) and pharmacological interventions, together with the improvement in metabolic health. Finally, novel therapeutics developed to target mitochondria have potential for a more integrative therapeutic approach, treating both causative and secondary defects of diabetes.

Keywords: blood cells; diabetes therapy; exercise; insulin resistance; liver; mitochondria; respiration; respiratory capacity; skeletal muscle; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Cellular mechanisms underlying exercise as lifestyle intervention in T2D. Exercise increases insulin sensitivity in T2D by affecting energy metabolism through induction of mitochormesis, stimulation of mitochondrial turnover and biogenesis, increase in Ca2+ concentration, AMP/ATP and NAD+/NADH ratios and increase in respiration: ROUTINE, LEAK, OXPHOS and ET capacity. Symbol: ↑ = increase.
Figure 2
Figure 2
Potential mitochondria targeting agents that might improve insulin sensitivity through modulation of mitochondrial function. They are grouped based on the strategy of their pharmacological actions, which implies potential molecular mechanisms: NBMs (NAD+ boosting molecules), mitochondrial membrane properties modulators, STACs (Sirt1-activating compounds), OXPHOS modulators, AMPK activators, PPAR agonists, antioxidants (ROS scavenger), MCP (mitochondrial pyruvate carrier) inhibitors, CI (respiratory complex I) inhibitors, mPTP (mitochondrial permeability transition pore) inhibitors, CoQ10 (coenzyme Q10) analogues, mitochondrial-associated ER membranes (MAM) modulators and novel drugs to be designed. Symbols: ? = unknown drug—to be designed; ↑ = increase.
Figure 3
Figure 3
Mitochondria as an effector target of main diabetogenic factors such as obesity, aging and sedentary habits, which all cause a decrease of respiratory capacity, while the lifestyle and pharmacological interventions cause an increase of respiratory capacity and improvement of metabolic health.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., Unwin N., Colagiuri S., Guariguata L., Motala A.A., Ogurtsova K., et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res. Clin. Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843. - DOI - PubMed
    1. A DeFronzo R. Lilly lecture: The triumvirate: Beta cell, muscle, liver, a collusion responsible for NIDDM. Diabetes. 1988;37:667–687. doi: 10.2337/diab.37.6.667. - DOI - PubMed
    1. DeFronzo R.A. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes. 2009;58:773–795. doi: 10.2337/db09-9028. - DOI - PMC - PubMed
    1. Lowell B.B. Mitochondrial Dysfunction and Type 2 Diabetes. Science. 2005;307:384–387. doi: 10.1126/science.1104343. - DOI - PubMed
    1. Montgomery M.K., Turner N. Mitochondrial dysfunction and insulin resistance: An update. Endocr. Connect. 2015;4:R1–R15. doi: 10.1530/EC-14-0092. - DOI - PMC - PubMed

Substances